Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6, before market open.The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $11.56 billion and $1.46 per share, respectively.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Earnings estimate for 2024 has increased to 92 cents from 91 cents per share over the past 60 days. It’s worth noting that the annual earnings estimate has ...

Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.46 per share in its upcoming release, pointing to a year-over-year decline of 14.1%. It is anticipated that revenues will amount to $11.56 billion, exhibiting an increase of 0.7% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 7.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their ...

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive. Some excellent, highly profitable corporations offer both a higher-than-average yield and a business that can sustain a dividend program for a long time.Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's c ...

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which w ...

Core Insights - Bristol Myers Squibb (BMY) is positioned to continue its earnings-beat streak, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 23.51% [1][3] Earnings Performance - In the last reported quarter, Bristol Myers achieved earnings of $1.80 per share, surpassing the Zacks Consensus Estimate of $1.49 per share, resulting in a surprise of 20.81% [2] - For the previous quarter, the company was expected to report earnings of $1.64 per share but delivered $2.07 per share, yielding a surprise of 26.22% [2] Earnings Estimates and Predictions - Estimates for Bristol Myers have been trending upward, influenced by its history of earnings surprises [3] - The company currently has a positive Earnings ESP of +0.43%, indicating that analysts are optimistic about its earnings prospects [6] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong possibility of another earnings beat in the upcoming report [6] Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [4] - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [5] Future Outlook - The next earnings report for Bristol Myers is anticipated to be released on February 6, 2025 [6]

Company Overview - Bristol Myers Squibb (BMY) is expected to report a year-over-year decline in earnings with a projected EPS of $1.46, reflecting a decrease of 14.1% compared to the previous year [3] - Revenue for the quarter is anticipated to be $11.57 billion, which represents a slight increase of 0.8% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 7.02% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Bristol Myers is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.43%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Historical Performance - In the last reported quarter, Bristol Myers exceeded the expected EPS of $1.49 by delivering $1.80, achieving a surprise of +20.81% [12] - The company has successfully beaten consensus EPS estimates in the last four quarters [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Qiagen (QGEN) is also expected to report earnings of $0.62 per share, reflecting a year-over-year increase of 12.7% [17] - Qiagen's revenue is projected to be $520.73 million, up 2.3% from the previous year, with an Earnings ESP of 2.76% indicating a likely earnings beat [18]

Group 1 - The article identifies 10 undervalued dividend growth stocks for further research and potential investment, emphasizing their quality scores as a basis for selection [1] - The author recommends investing in dividend growth stocks and writing options to enhance dividend income, highlighting a portfolio named DivGro that focuses on such stocks [1] - The article is part of a monthly series aimed at providing insights into dividend growth investing, stock selection, and passive income generation [1] Group 2 - The author has a beneficial long position in the shares of HSY, HRL, and VZ, indicating a personal investment interest in these stocks [2] - The article expresses the author's opinions without any compensation from companies mentioned, ensuring an unbiased perspective [2] - There is a disclaimer regarding past performance not guaranteeing future results, emphasizing the independent nature of the analysis [3]

Core Viewpoint - Many stocks, including those in the S&P 500, offer low dividend yields, averaging just 1.3%, making it challenging for income investors to generate significant returns from dividends [1] Group 1: Investment Opportunities - Bristol Myers Squibb is highlighted as a top healthcare investment with a focus on drug development, recently receiving FDA approval for Cobenfy, which could generate $7.5 billion at peak revenue, and expanding the use of Breyanzi, potentially generating $2 billion [4][5] - Target is identified as a Dividend King with over 50 consecutive years of dividend increases, currently yielding 2.9%, despite a 34% decline in share price over the past three years [6][8] - Suncor Energy, a major player in the oil and gas industry, has seen a nearly 40% increase in value over the past three years and generated CA$54.8 billion ($38.08 billion) in revenue, with a forward P/E of 14 and a dividend yield of 4.1% [9][10][11] Group 2: Financial Performance - Bristol Myers Squibb is trading at less than 9 times projected earnings for the next year, indicating potential value for investors [5] - Target has maintained flat revenue over the past three quarters but has grown earnings by over 8%, suggesting resilience despite economic headwinds [7] - Suncor's operating profit over the last 12 months was CA$9.6 billion ($6.67 billion), reflecting strong financial performance and a disciplined capital program aimed at increasing production and lowering costs [10][11]

Company Performance - Bristol Myers Squibb (BMY) closed at $60.62, reflecting a +1.59% change from the previous day's closing price, outperforming the S&P 500's daily loss of 1.46% [1] - Over the past month, BMY shares have increased by 3.45%, surpassing the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% [1] Upcoming Earnings - The company's earnings report is scheduled for February 6, 2025, with projected earnings of $1.46 per share, indicating a year-over-year decline of 14.12% [2] - Revenue is expected to reach $11.56 billion, representing a 0.76% increase compared to the same quarter last year [2] Analyst Estimates - Recent changes to analyst estimates for Bristol Myers Squibb are being closely monitored, as they often indicate shifts in near-term business trends [3] - Positive estimate revisions are interpreted as favorable signs for the company's business outlook [3] Zacks Rank and Valuation - The Zacks Rank system, which evaluates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 1.61% in the past month [5] - The company has a Forward P/E ratio of 8.44, which is significantly lower than the industry average of 22.83, and a PEG ratio of 2.11 compared to the industry average of 1.36 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 70, placing it in the top 28% of over 250 industries [7] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Bristol Myers Squibb identifies Alzheimer's disease as the largest market opportunity for its newly approved schizophrenia drug, Cobenfy, which is expected to generate billions in revenue [1][2]. Market Potential - Each treatment application for Cobenfy, including Alzheimer's-related psychosis, agitation, cognition, bipolar disorder, and autism, has multibillion-dollar potential, with Alzheimer's being the most significant market [2]. - There are nearly 6 million Alzheimer's patients in the U.S., with approximately half experiencing psychosis, making Cobenfy a potential first drug specifically approved for this condition [3]. Treatment Advantages - Current atypical antipsychotics used for treating Alzheimer's psychosis are not approved for this purpose and can increase mortality risk, whereas Cobenfy does not carry this risk [4]. - Alzheimer's agitation affects an estimated 60% to 70% of Alzheimer's patients, indicating a substantial need for effective treatment options [4]. Development Timeline - Bristol Myers Squibb plans to release initial late-stage trial data for Cobenfy in treating Alzheimer's-related psychosis by the end of the year, ahead of previous expectations [5]. - Phase three trials for Alzheimer's agitation, cognition, and bipolar disorder are expected to start in 2025, with autism studies commencing in 2026 [5]. Financial Projections - JPMorgan analyst estimates Cobenfy sales could reach approximately $5 billion by 2030, with peak sales potential in the $10 billion range across various treatment applications, providing significant revenue support for Bristol Myers Squibb amid patent expirations of top-selling treatments [6].